Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Purinethol · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Mercaptopurine 50 mg |
| 2 | ACTIVE_COMPARATOR | Purinethol® Tablets 50 mg |
| Name | Type | Description |
|---|---|---|
| Mercaptopurine 50 mg | DRUG | 50mg, single dose fasting |
| Purinethol® Tablets 50 mg | DRUG | 50mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male 3. Volunteers are to be sterile (documentation required) or during the course of the study, from study screen until 3 months after study exit, non-sterile male volunteers must use a spermicide-containing barrier method of contraception to...
Purinethol is a small molecule drug being studied in healthy volunteers. It is currently in Phase 1 clinical development, with one completed trial involving 60 participants. The drug is being developed by Viatris Inc. (VTRS).
Purinethol is being developed by Viatris Inc., a company traded on the stock exchange under the ticker VTRS. The drug is currently in Phase 1 clinical development.
Purinethol is in Phase 1 clinical development. It has one completed trial with 60 healthy male participants. The drug is investigational and has not been approved by regulatory authorities.
Purinethol has one completed clinical trial, NCT00648336, titled 'Fasting Study of Mercaptopurine 50 mg and Purinethol Tablets 50 mg'. This Phase 1 study enrolled 60 healthy male participants in the United States.
Purinethol is being studied in a clinical trial that compares it to mercaptopurine 50 mg tablets. The trial NCT00648336 is a fasting study that evaluates both Purinethol and mercaptopurine in healthy volunteers.